New hope for breast cancer brain metastases: targeted drug Trop-2 ADC under study
NCT ID NCT07251868
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a drug called sacituzumab govitecan (Trop-2 ADC) in 100 breast cancer patients whose cancer has spread to the brain. Researchers want to see if the drug can shrink brain tumors and delay disease progression, while also monitoring side effects. The study collects data from routine care across multiple hospitals, without assigning patients to different treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab govitecan (a Trop-2 antibody-drug conjugate)
What this could lead to
If successful, this could show that sacituzumab govitecan is an effective treatment option for breast cancer that has spread to the brain, potentially improving control of brain tumors.
What could go wrong
This is an early real-world study without a control group, so results may be less reliable. The drug may cause side effects, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••